Evidence method
Level · gp.fundamentals.capex_revenue_ratio
11.36% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ADPT · Sep 30, 2022
Adaptive Biotechnologies Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-22-021923General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-88.66% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
21.19% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
36.26% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
68.83% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-94.98% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
74.55% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
29.57% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesSelf-history eligible
Sep 30, 20217/8 normalizedLevel 3Dec 31, 20217/8 normalizedLevel 3Mar 31, 20227/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/9 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/9 normalizedLevel 3Mar 31, 20258/9 normalizedLevel 3Jun 30, 20258/9 normalizedLevel 3Sep 30, 20258/9 normalizedLevel 3Dec 31, 20258/9 normalizedLevel 3Mar 31, 20268/9 normalizedLevel 3Jun 30, 20268/9 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 12.13%
- Current
- 11.36%
- Delta
- -0.78%
- Previous
- -107.80%
- Current
- -88.66%
- Delta
- 19.13%
- Previous
- 13.39%
- Current
- 21.19%
- Delta
- 7.80%
- Previous
- 43.01%
- Current
- 36.26%
- Delta
- -6.75%
- Previous
- 69.72%
- Current
- 68.83%
- Delta
- -0.88%
- Previous
- -120.25%
- Current
- -94.98%
- Delta
- 25.27%
- Previous
- 84.83%
- Current
- 74.55%
- Delta
- -10.28%
- Previous
- 32.48%
- Current
- 29.57%
- Delta
- -2.91%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ADPT Fundamental State →Analogous To · ADPT state analogue 4 →Has State · Adaptive Biotechnologies Corp →Transitioned To · ADPT Fundamental State →Transitioned To · ADPT CAPEX_INTENSITY_DECREASED →Transitioned To · ADPT CASH_GENERATION_INCREASED →Transitioned To · ADPT GROWTH_INCREASED →Transitioned To · ADPT INVENTORY_PRESSURE_DECREASED →Transitioned To · ADPT MARGIN_DECREASED →Transitioned To · ADPT PROFITABILITY_INCREASED →Transitioned To · ADPT R_AND_D_INTENSITY_DECREASED →Transitioned To · ADPT SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.